In a report published Friday, Citigroup reiterated its Buy rating on Covidien Ltd. (NYSE: COV), and raised its price target from $64.00 to $68.00.Citigroup noted, ’The 2012 investor meeting was ...
Read more
In a report published Wednesday, the Goldman Sachs Group reiterated its Sell rating on Aetna (NYSE: AET), but lowered its price target from $43.00 to $41.00.Goldman Sachs noted, ’So far, ...
Read more
